Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News biOasis Technologies Ord Shs BIOAF

Primary Symbol: V.BTI.H

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in... see more

Add To Watchlist

Recent & Breaking News (TSXV:BTI.H)

biOasis Announces Oversubscription of Financing

MarketWire Canada March 31, 2017

biOasis Provides AGM Update -- Expanding The biOasis Deal Flow Pipeline

MarketWire Canada January 22, 2017

The Biggest Big Tobacco Companies

Benzinga.com January 18, 2017

British American's Acquisition Of Reynolds Makes It Jefferies' Preferred Global Tobacco Play

Benzinga.com January 17, 2017

The Market In 5 Minutes: Morgan Stanley Beats Estimates, Disney And Netflix Get Big Upgrades

Benzinga.com January 17, 2017

Wells Fargo: Chance Of A Philip Morris-Altria Merger Now 70%

Benzinga.com December 19, 2016

biOasis Attends BIO Europe and the Lockman BT2111 Paper is Honored by being Featured on the Cover of Pharmaceutical Research's December Journal

MarketWire Canada November 6, 2016

biOasis Engages Rising Tide Equity to Increase Global Awareness

MarketWire Canada October 23, 2016

biOasis Enters Into a License Agreement With Vaccinex Inc.

MarketWire Canada September 20, 2016

biOasis Announces Publication of Scientific Paper -- Transcend-Based Anti-Cancer Antibody BT2111 Crosses the Blood-Brain Barrier and Shows Efficacy in the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brains of Animal Model

MarketWire Canada August 29, 2016

biOasis Announces the Issuance of an Additional US Patent for the Delivery of Therapeutic Agents Across the Blood-Brain Barrier

MarketWire Canada July 10, 2016

biOasis Technologies Inc. to Present at BIO International Conference in San Francisco on June 7, 2016

Marketwired May 17, 2016

biOasis Technologies Enters Into a License Agreement With Astellas Research Institute of America LLC

Marketwired April 21, 2016

biOasis to Present at the Brains for Brain 10th Annual Workshop and Open Conference in Madrid, Spain

Marketwired March 17, 2016

biOasis Announces Shares for Services Settlement

Marketwired February 29, 2016

biOasis Technologies Inc. to Present at the 1st Annual Neuroscience BioPartnering and Investment Forum in New York on February 23, 2016

Marketwired February 11, 2016

biOasis Announces the Issuance of a US Patent for the Delivery of Therapeutic Agents Across the Blood-Brain Barrier Using Polypeptides Derived From the Transcend Protein Delivery Vector

Marketwired November 29, 2015

biOasis Announces Listing on OTCQB Exchange

Marketwired September 28, 2015

biOasis Announces Extension of Share Purchase Warrants

Marketwired August 14, 2015

biOasis Announces the Successful Delivery to the CNS of an Enzyme Used to Treat Hunter Syndrome

Marketwired July 31, 2015